Voyager Therapeutics (VYGR) EBT (2014 - 2026)

Voyager Therapeutics has disclosed EBT across 13 years of filings, most recently posting -$27.9 million for Q1 2026.

• EBT for Q1 2026 came in at -$27.9 million, up 9.88% year-over-year; the trailing twelve-month figure through Mar 2026 was -$116.5 million (down 38.7% YoY), and the FY2025 annual result was -$119.6 million, down 85.86% from the prior year.
• EBT came in at -$27.9 million for Q1 2026 at Voyager Therapeutics, down from -$27.4 million in the prior quarter.
• In the past five years, EBT ranged from a high of $124.7 million in Q1 2023 to a low of -$33.9 million in Q4 2024.
• The 5-year median for EBT is -$22.1 million (2023), against an average of -$7.3 million.
• Across the five-year window, EBT tumbled 566.69% in 2022 and surged 685.15% in 2023, its largest moves.
• Voyager Therapeutics' EBT stood at -$23.6 million in 2022, then jumped by 342.34% to $57.2 million in 2023, then tumbled by 159.25% to -$33.9 million in 2024, then rose by 19.13% to -$27.4 million in 2025, then retreated by 1.85% to -$27.9 million in 2026.
• The last three EBT figures came in at -$27.9 million (Q1 2026), -$27.4 million (Q4 2025), and -$27.8 million (Q3 2025), per Business Quant data.